

12 June 2025

FY2025 Business Update Webinar

Bioxyne Limited (ASX: BXN) (Bioxyne or Company) invites you to a Business Update Webinar, presented by Managing Director and Founder Sam Watson.

Date: Wednesday 18th June 2025
Time: 5:00PM AEST (SYDNEY)

Webinar Registration Link:

<https://events.teams.microsoft.com/event/11787e7e-c232-4635-82f8-20a1309e14cb@6250ea43-b31c-4d3a-b60e-bba1d573338a>

Key Discussion Points:

- Full year FY2025 revenue guidance
- Australian performance update
- UK market progress
- EU market progress
- MDMA Developments

Positive Outlook for FY2026

Bioxyne is positioned for continued growth in FY2026, attributable to further expansion of its business in Australia as well as entry into new high-growth opportunity markets including the UK, Germany and other EU countries.

The Company expects to deliver guidance for FY2026 in August.

This announcement has been approved by the Board for lodgement with the ASX.

About Bioxyne Limited:

Bioxyne Limited is an Australian pharmaceutical company focused on the development and commercialization of innovative medicines and active pharmaceutical ingredients.

For further information, please contact:

Bioxyne Limited
Investor Relations
Email: info@bioxyne.com
Phone: +61 2 9078 8180
Website: www.bioxyne.com

About Bioxyne

Bioxyne Limited (ASX:BXN) is an Australian-headquartered international consumer health and pharmaceutical company (incorporated in 2000) with a focus on clinically effective health and wellness products, psychotropic and investigational medicines.

About Breathe Life Sciences (BLS)

Breathe Life Sciences (“BLS”) is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances (S3, S4, S8, S9), including medicinal cannabis, Psilocybin, and MDMA.

BLS was founded in 2018 and has quickly expanded into a multi-national business focused on alternative therapeutics and investigational medicines. The company’s corporate head office is in Sydney, with operations and licensed manufacturing, warehousing, import/export, sales and distribution centres in Queensland (Australia), Nagoya (Japan), Manchester (UK), and Prague (Czechia).

The BLS business model is focused on manufacturing final dose form medicines, sales and distribution. BLS sources raw materials and API from suppliers in 5 continents and is the Australian market leading manufacturer of therapeutic goods including cannabis, MDMA, and Psilocybin.

Outside of Australia the BLS Group operates in pharmaceuticals, medical cannabis, consumer health products, and novel foods (CBD). In the UK, Europe and Japan, the Company engages in the following activities:

- a) Owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand. Internationally recognized for its cannabis-based food supplements, lifestyle products, functional mushrooms and nootropics, and prescription medicines in Australia.
- b) Contract manufacture and wholesale of raw materials and cannabinoid extracts in Japan, UK and Europe.
- c) Contract / white label manufacture of consumer health products for brands in Japan, UK and Europe in company-owned facilities.
- d) Research and development of novel medicines.
- e) Direct sales via online and wholesale of BLS-owned consumer brands, such as Dr Watson®
 - **United Kingdom:** drwatsoncbd.com
 - **Japan:** nolcbrn.com
 - **UK / EU:** breathelifesciences.com
- f) Export and supply of medicinal cannabis products and manufacturing services to UK and European markets.

Corporate: bioxyne.com

Australia: bls.com.au

International: breathelifesciences.com

